This article is more than 5 years old. Information may no longer be current.

Novel radiotherapy for liver cancer demonstrates complete, partial responses

Nanobiotix announced positive results of the NBTXR3 activated by stereotactic body radiation, or SBRT, for the treatment of hepatocellular carcinoma and liver metastasis, according to a press release.

“The patient population in this study has significant unmet needs primarily due to pre-existing issues with hepatic function,” Enrique Chajon, MD, study investigator from the Centre Eugene Marquis in France, said during a presentation at ASTRO 2019. “When you combine that with the fact that there is low life expectancy for this group, you have a critical need for innovative treatment solutions. These data provide promising evidence that NBTXR3 activated by SBRT could be a valuable option with excellent safety and increased efficacy, presenting a new way to improve outcomes for these patients.”

The phase 1 study comprised 11 patients with HCC who were incapable of undergoing local surgery or local treatment and had a minimum life expectancy of 3 months, as well as six patients with liver metastasis with unresectable tumors and a minimum life expectancy of 6 months.

Results showed that 62.5% of evaluable patients with HCC had a complete response and the rest had a partial response. Half of the patients with liver metastasis had partial response and the other 50% showed stable disease.

Investigators also noted that NBTXR3 activated by SBRT had a similar safety profile to SBRT alone with no dose-limiting toxicity and the treatment remained in the injected tumor with no leakage to surrounding tissue.

Nanobiotix expects results for all patients in the first quarter of 2020.

Reference: www.nanobiotix.com